{
    "info": {
        "nct_id": "NCT03477110",
        "official_title": "SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study",
        "inclusion_criteria": "* Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma\n* Karnofsky performance status (KPS) ≥ 60\n* Patients must have recovered from the effects of surgery per treating physician's judgment; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment; for core or needle biopsy, a minimum of 14 days must have elapsed prior to the day of protocol treatment\n* Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3\n* Platelets ≥ 100,000 cells/mm^3\n* Hemoglobin ≥ 9.0 g/dl\n* Creatinine clearance > 30 mL/min\n* Bilirubin < 2.0 mg/dL\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal range\n* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose of temozolomide\n* Is able to have magnetic resonance imaging (MRI) with contrast of the brain\n* All subjects must be able to comprehend and sign a written informed consent document. If the subject can comprehend the informed consent but is unable to sign, a LAR may sign the written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Infratentorial disease (defined as glioblastoma [GBM] derived from cerebellum or brainstem)\n* Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias\n* A skull defect (such as, missing bone with no replacement)\n* Women of childbearing potential who are pregnant or breastfeeding\n* Evidence of increased intracranial pressure (midline shift > 5 mm, clinically significant papilledema)\n* Serious medical or psychiatric illness likely to interfere with participation in this clinical study, in the opinion of the investigator\n* Prior radiation treatment to the brain\n* Prior treatment with temozolomide\n* Known hypersensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes\n* Known active collagen vascular disease",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance > 30 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance > 30 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is able to have magnetic resonance imaging (MRI) with contrast of the brain",
            "criterions": [
                {
                    "exact_snippets": "Is able to have magnetic resonance imaging (MRI) with contrast of the brain",
                    "criterion": "ability to undergo brain MRI with contrast",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin < 2.0 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin < 2.0 mg/dL",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 100,000 cells/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 100,000 cells/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "cells/mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose of temozolomide",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential",
                    "criterion": "child-bearing potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose of temozolomide",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "hormonal",
                                "barrier method of birth control",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "prior to study entry and for 4 months after last dose of temozolomide"
                        }
                    ]
                },
                {
                    "exact_snippets": "men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose of temozolomide",
                    "criterion": "contraception use (male)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "hormonal",
                                "barrier method of birth control",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "prior to study entry and for 4 months after last dose of temozolomide"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 9.0 g/dl",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9.0 g/dl",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test",
                    "criterion": "beta-human chorionic gonadotropin (HCG) pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "documented within 14 days prior to registration",
                    "criterion": "timing of pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "time before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky performance status (KPS) ≥ 60",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance status (KPS) ≥ 60",
                    "criterion": "Karnofsky performance status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All subjects must be able to comprehend and sign a written informed consent document. If the subject can comprehend the informed consent but is unable to sign, a LAR may sign the written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "must be able to comprehend ... informed consent document",
                    "criterion": "comprehension of informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be able to ... sign a written informed consent document ... If the subject ... is unable to sign, a LAR may sign",
                    "criterion": "ability to sign informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "alternative",
                            "expected_value": "LAR may sign if subject is unable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have recovered from the effects of surgery per treating physician's judgment; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment; for core or needle biopsy, a minimum of 14 days must have elapsed prior to the day of protocol treatment",
            "criterions": [
                {
                    "exact_snippets": "Patients must have recovered from the effects of surgery per treating physician's judgment",
                    "criterion": "recovery from effects of surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "physician_judgment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "there must be a minimum of 21 days from the day of surgery to the day of protocol treatment",
                    "criterion": "interval from surgery to protocol treatment",
                    "requirements": [
                        {
                            "requirement_type": "time_since_surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for core or needle biopsy, a minimum of 14 days must have elapsed prior to the day of protocol treatment",
                    "criterion": "interval from core or needle biopsy to protocol treatment",
                    "requirements": [
                        {
                            "requirement_type": "time_since_biopsy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma",
            "criterions": [
                {
                    "exact_snippets": "pathology confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "pathology"
                        }
                    ]
                },
                {
                    "exact_snippets": "newly diagnosed",
                    "criterion": "diagnosis recency",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "World Health Organization (WHO) grade IV glioma",
                    "criterion": "glioma grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "IV"
                        },
                        {
                            "requirement_type": "classification_system",
                            "expected_value": "World Health Organization (WHO)"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior radiation treatment to the brain",
            "criterions": [
                {
                    "exact_snippets": "Prior radiation treatment to the brain",
                    "criterion": "radiation treatment to the brain",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias",
            "criterions": [
                {
                    "exact_snippets": "Implanted pacemaker",
                    "criterion": "pacemaker implantation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "defibrillator",
                    "criterion": "defibrillator implantation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "deep brain stimulator",
                    "criterion": "deep brain stimulator implantation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented clinically significant arrhythmias",
                    "criterion": "clinically significant arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious medical or psychiatric illness likely to interfere with participation in this clinical study, in the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Serious medical or psychiatric illness likely to interfere with participation in this clinical study",
                    "criterion": "serious medical or psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "likelihood to interfere with participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator opinion",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "investigator judgment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Infratentorial disease (defined as glioblastoma [GBM] derived from cerebellum or brainstem)",
            "criterions": [
                {
                    "exact_snippets": "Infratentorial disease (defined as glioblastoma [GBM] derived from cerebellum or brainstem)",
                    "criterion": "infratentorial disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "glioblastoma [GBM] derived from cerebellum or brainstem",
                    "criterion": "glioblastoma (GBM) location",
                    "requirements": [
                        {
                            "requirement_type": "origin",
                            "expected_value": [
                                "cerebellum",
                                "brainstem"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes",
                    "criterion": "hypersensitivity to conductive hydrogels",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active collagen vascular disease",
            "criterions": [
                {
                    "exact_snippets": "Known active collagen vascular disease",
                    "criterion": "collagen vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A skull defect (such as, missing bone with no replacement)",
            "criterions": [
                {
                    "exact_snippets": "A skull defect (such as, missing bone with no replacement)",
                    "criterion": "skull defect",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with temozolomide",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with temozolomide",
                    "criterion": "temozolomide treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential who are pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential who are ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of increased intracranial pressure (midline shift > 5 mm, clinically significant papilledema)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of increased intracranial pressure",
                    "criterion": "increased intracranial pressure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "midline shift > 5 mm",
                    "criterion": "midline shift",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant papilledema",
                    "criterion": "papilledema",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal range",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) < 3 x upper limit of normal range",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x upper limit of normal range"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) < 3 x upper limit of normal range",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x upper limit of normal range"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}